Faster Transition From Intravenous to Oral Antihypertensives Associated With Improved Outcomes After Aortic Dissection
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Pharmacotherapy"
DOI: 10.1177/1060028019870181
Abstract: Background: After stabilization with intravenous (IV) antihypertensives, the impact of speed-of-transition from IV to enteral (PO) medications in the intensive care unit (ICU) is unknown. Objective: To assess ICU length of stay (LOS) based on… read more here.
Keywords: intravenous oral; faster transition; transition; aortic dissection ... See more keywords
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.02418-2019
Abstract: Prostacyclin analogues targeting the prostacyclin pathway are used to treat patients with pulmonary arterial hypertension (PAH), and are given either by an intravenous, subcutaneous or inhaled route [1]. Continuous i.v. infusion of epoprostenol has received… read more here.
Keywords: pulmonary arterial; transition intravenous; epoprostenol; arterial hypertension ... See more keywords
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0261336
Abstract: Subcutaneous (SC) administration of rituximab provides an opportunity for reduced patient treatment burden and increased healthcare efficiencies as an alternative to intravenous (IV) rituximab. There is minimal evidence comparing costs associated with SC and IV… read more here.
Keywords: health; transition intravenous; intravenous subcutaneous; assessing transition ... See more keywords